Skip to main content

AstraZeneca to buy California biotech firm TeneoTwo for up to $1.27 billion

The key asset to be acquired in the deal, which includes an $100 million upfront payment, is a new drug candidate that targets non-Hodgkin's lymphoma.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.